Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- Quality Adjusted Life Years
- QALY
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in this website by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 8 | 9 |
| 2015 | 1 | 2 | 3 |
| 2016 | 0 | 7 | 7 |
| 2017 | 0 | 3 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, O'Dea R, Schackman BR, White LF, Linas BP. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Netw Open. 2024 Oct 01; 7(10):e2437233.
-
O'Callaghan L, Chertavian E, Johnson SJ, Ferries E, Deligiannidis KM. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States. J Med Econ. 2024 Jan-Dec; 27(1):492-505.
-
Reynolds MR, Stein AB, Sun X, Hytopoulos E, Steinhubl SR, Cohen DJ. Cost-Effectiveness of AF Screening With 2-Week Patch Monitors: The mSToPS Study. Circ Cardiovasc Qual Outcomes. 2023 11; 16(11):e009751.
-
Wang L, Lauren BN, Hager K, Zhang FF, Wong JB, Kim DD, Mozaffarian D. Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.
-
Coute RA, Nathanson BH, DeMasi S, Mader TJ, Kurz MC. Disability-Adjusted Life Years Due to Pediatric Out-of-Hospital Cardiac Arrest in the United States: A CARES Surveillance Group Study. Circ Cardiovasc Qual Outcomes. 2023 05; 16(5):e009786.
-
Yang DD, Borsky K, Jani C, Crowley C, Rodrigues JN, Matin RN, Marshall DC, Salciccioli JD, Shalhoub J, Goodall R. Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017. Br J Dermatol. 2023 02 10; 188(2):237-246.
-
Elkind MSV, Witte KK, Kasner SE, Sawyer LM, Grimsey Jones FW, Rinciog C, Tsintzos S, Rosemas SC, Lanctin D, Ziegler PD, Reynolds MR. Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US. BMC Cardiovasc Disord. 2023 01 25; 23(1):45.
-
Modi RM, Liu CL, Isaza N, Raber I, Calvachi P, Zimetbaum P, Bellows BK, Kramer DB, Kazi DS. Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure. Circ Cardiovasc Qual Outcomes. 2022 03; 15(3):e008443.
-
Ito K, Chapman R, Pearson SD, Tafazzoli A, Yaffe K, Gurwitz JH. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors. JAMA Netw Open. 2021 10 01; 4(10):e2129392.
-
Goodall R, Alazawi A, Hughes W, Bravis V, Salciccioli JD, Marshall DC, Crowley C, Shalhoub J. Trends in type 2 diabetes mellitus disease burden in European Union countries between 1990 and 2019. Sci Rep. 2021 07 28; 11(1):15356.